<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0390</journal-id>
<journal-title><![CDATA[Revista Médica del Uruguay]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Méd. Urug.]]></abbrev-journal-title>
<issn>1688-0390</issn>
<publisher>
<publisher-name><![CDATA[Sindicato Médico del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-03902026000101205</article-id>
<article-id pub-id-type="doi">10.29193/rmu.42.1.11</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Terapia con 177Lutecio-PSMA-617 en el tratamiento de pacientes con cáncer de próstata metastásico hormono-resistente: primera experiencia en Uruguay]]></article-title>
<article-title xml:lang="en"><![CDATA[Therapy with 177Lu-PSMA-617 in the treatment of patients with hormone-resistant metastatic prostate cancer: first experience in Uruguay]]></article-title>
<article-title xml:lang="pt"><![CDATA[Terapia com 177Lu-PSMA-617 no tratamento de pacientes com câncer de próstata metastático resistente à hormonioterapia: primeira experiência no Uruguai]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[dos Santos]]></surname>
<given-names><![CDATA[Gerardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silvera]]></surname>
<given-names><![CDATA[Enzo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vera]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gambini]]></surname>
<given-names><![CDATA[Juan Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[Omar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro Uruguayo de Imagenología Molecular  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Clínicas Dr. Manuel Quintela  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional del Cáncer  ]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro Asistencial del Sindicato Médico del Uruguay  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<volume>42</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-03902026000101205&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-03902026000101205&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-03902026000101205&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: El 177Lu-PSMA-617 es una nueva terapia con radioligandos que se utiliza en pacientes con cáncer de próstata metastásico hormonorresistente.  Objetivos: Valorar la factibilidad, respuesta, eficacia y el perfil de seguridad/toxicidad del tratamiento del 177Lu-PSMA-617 en esta población de pacientes.  Materiales y métodos: Entre octubre de 2017 y febrero de 2022, 19 pacientes (edad: media de 67,8 años; PSA: media de 287 ng/mL) recibieron terapia 177Lu-PSMA-617. Evaluamos la respuesta clínica, la respuesta a la terapia, los eventos adversos y la dosimetría.  Resultados: Todos los pacientes recibieron de 1 a 5 dosis (actividad media 7,1 GBq/ciclo) cada 6-8 semanas (1 ciclo n=3, 2 ciclos n=1, 3 ciclos n=13, 4 ciclos n=1 y 5 ciclos n=1). 15 pacientes (79%) completaron tres ciclos de terapia. Previo a la terapia, todos los pacientes mostraron lesiones metastásicas ávidas de PSMA en el PET/CT con 68Ga-PSMA-11. En cuanto a la respuesta del PSA, 5 pacientes mostraron respuesta bioquímica, 3 pacientes enfermedad estable y 7 pacientes mostraron enfermedad progresiva. 7 de 15 pacientes (46,6%) mostraron alguna disminución del PSA. En pacientes que completaron tres ciclos o más, el PET/CT mostró progresión de la enfermedad (n=9) y remisión parcial (n=5). Documentamos alivio del dolor/reducción del uso de analgésicos (n=9), xerostomía (n=2), náuseas (n=3), fatiga (n=6) y trombocitopenia (n=2). No se demostró hepatotoxicidad ni nefrotoxicidad. Se confirmó la seguridad de 177Lu-PSMA-617 para tejidos no diana, mostrando dosis absorbidas medias (Gy) por debajo de las recomendadas en órganos críticos.  Conclusiones: Concluimos que la terapia con 177Lu-PSMA-617 es una opción terapéutica segura y bien tolerada para pacientes con cáncer de próstata metastásico hormonorresistente (CPMHR), con impacto positivo en la calidad de vida de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: 177Lu-PSMA-617 is a novel radioligand therapy used in patients with metastatic castration-resistant prostate cancer.  Objectives: To assess the feasibility, response, efficacy, and safety/toxicity profile of 177Lu-PSMA-617 treatment in this patient population.  Materials and Methods: Between October 2017 and February 2022, 19 patients (age: mean 67.8 years; PSA: mean 287 ng/mL) received 177Lu-PSMA-617 therapy. We evaluated clinical response, treatment response, adverse events, and dosimetry.  Results: All patients received between 1 and 5 cycles (mean activity 7.1 GBq per cycle) every 6&#8211;8 weeks (1 cycle n=3, 2 cycles n=1, 3 cycles n=13, 4 cycles n=1, and 5 cycles n=1). 15 patients (79%) completed three cycles of therapy. Prior to treatment, all patients showed PSMA-avid metastatic lesions on 68Ga-PSMA-11 PET/CT. Regarding PSA response, 5 patients showed a biochemical response, 3 patients had stable disease, and 7 patients showed progressive disease. 7 of 15 patients (46.6%) showed some reduction in PSA levels. In patients who completed three or more cycles, PET/CT showed disease progression (n=9) and partial remission (n=5). We documented pain relief and/or reduced analgesic use (n=9), xerostomia (n=2), nausea (n=3), fatigue (n=6), and thrombocytopenia (n=2). No hepatotoxicity or nephrotoxicity was observed. The safety of 177Lu-PSMA-617 for non-target tissues was confirmed, with mean absorbed doses (Gy) below the recommended limits for critical organs.  Conclusions: We conclude that 177Lu-PSMA-617 therapy is a safe and well-tolerated therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC), with a positive impact on patients&#8217; quality of life.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[ Introdução: O 177Lu-PSMA-617 é uma nova terapia com radioligantes utilizada em pacientes com câncer de próstata metastático resistente à castração.  Objetivos: Avaliar a factibilidade, a resposta, a eficácia e o perfil de segurança/toxicidade do tratamento com 177Lu-PSMA-617 nessa população de pacientes.  Materiales y métodos: Entre outubro de 2017 e fevereiro de 2022, 19 pacientes (idade: média de 67,8 anos; PSA: média de 287 ng/mL) receberam terapia com 177Lu-PSMA-617. Avaliamos a resposta clínica, a resposta ao tratamento, os eventos adversos e a dosimetria.  Resultados: Todos os pacientes receberam de 1 a 5 ciclos (atividade média de 7,1 GBq por ciclo) a cada 6&#8211;8 semanas (1 ciclo n=3, 2 ciclos n=1, 3 ciclos n=13, 4 ciclos n=1 e 5 ciclos n=1). 15 pacientes (79%) completaram três ciclos de terapia. Antes do tratamento, todos os pacientes apresentaram lesões metastáticas ávidas por PSMA no PET/CT com 68Ga-PSMA-11. Quanto à resposta do PSA, 5 pacientes apresentaram resposta bioquímica, 3 pacientes doença estável e 7 pacientes apresentaram doença progressiva. 7 de 15 pacientes (46,6%) apresentaram alguma redução nos níveis de PSA. Em pacientes que completaram três ciclos ou mais, o PET/CT demonstrou progressão da doença (n=9) e remissão parcial (n=5). Foram documentados, alívio da dor e/ou redução do uso de analgésicos (n=9), xerostomia (n=2), náuseas (n=3), fadiga (n=6) e trombocitopenia (n=2). Não foi demonstrada hepatotoxicidade nem nefrotoxicidade. A segurança do 177Lu-PSMA-617 para tecidos não alvo foi confirmada, com doses médias absorvidas (Gy) abaixo das recomendadas para órgãos críticos.  Conclusões: Concluímos que a terapia com 177Lu-PSMA-617 é uma opção terapêutica segura e bem tolerada para pacientes com câncer de próstata metastático resistente à castração (CPMRC), com impacto positivo na qualidade de vida dos pacientes.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de próstata metastásico hormono-resistente]]></kwd>
<kwd lng="es"><![CDATA[Theragnosis-diagnoterapia]]></kwd>
<kwd lng="es"><![CDATA[68Ga-PSMA-11]]></kwd>
<kwd lng="es"><![CDATA[177Lutecio-PSMA-617]]></kwd>
<kwd lng="es"><![CDATA[PET/CT]]></kwd>
<kwd lng="en"><![CDATA[Metastatic castration-resistant prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[Theragnostics&#8211; diagnostic]]></kwd>
<kwd lng="en"><![CDATA[68Ga-PSMA-11]]></kwd>
<kwd lng="en"><![CDATA[177Lutetium-PSMA-617]]></kwd>
<kwd lng="en"><![CDATA[PET/CT]]></kwd>
<kwd lng="pt"><![CDATA[Câncer de próstata metastático resistente à castração]]></kwd>
<kwd lng="pt"><![CDATA[Teragnóstica &#8211; abordagem]]></kwd>
<kwd lng="pt"><![CDATA[68Ga-PSMA-11]]></kwd>
<kwd lng="pt"><![CDATA[177Lutécio-PSMA-617]]></kwd>
<kwd lng="pt"><![CDATA[PET/CT]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="book">
<collab>Comisión Honoraria de Lucha Contra el Cáncer</collab>
<source><![CDATA[Situación epidemiológica del Uruguay en relación al cáncer]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[CHLCC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yap]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Zivi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Omlin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Bono]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The changing therapeutic landscape of castration-resistant prostate cancer]]></article-title>
<source><![CDATA[Nat Rev Clin Oncol]]></source>
<year>2011</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>597-610</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Golijanin]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Miyamoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Messing]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Androgen deprivation therapy for prostate cancer]]></article-title>
<source><![CDATA[Expert Opin Pharmacother]]></source>
<year>2008</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>211-28</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Debes]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Tindall]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of androgen-refractory prostate cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>351</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1488-90</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="book">
<collab>Fondo Nacional de Recursos</collab>
<source><![CDATA[Normativa de tratamiento del cáncer de próstata: tratamiento del cáncer de próstata metastásico hormonorresistente]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[FNR]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Emmett]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Willowson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Violet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blanksby]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lutetium 177PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy]]></article-title>
<source><![CDATA[J Med Radiat Sci]]></source>
<year>2017</year>
<volume>64</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>52-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmadzadehfar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wegen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yordanova]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fimmers]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kürpig]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eppard]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2017</year>
<volume>44</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1448-54</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kratochwil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Giesel]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Stefanova]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bene&#353;ová]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bronzel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Afshar-Oromieh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2016</year>
<volume>57</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1170-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hofman]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Violet]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hicks]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ferdinandus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Thang]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Akhurst]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2018</year>
<volume>19</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>825-33</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[GL Jr]]></given-names>
</name>
<name>
<surname><![CDATA[Haley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Beckett]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Schellhammer]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues]]></article-title>
<source><![CDATA[Urol Oncol]]></source>
<year>1995</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-28</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rajasekaran]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Moy]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Xia]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Constitutive and antibody-induced internalization of prostate-specific membrane antigen]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1998</year>
<volume>58</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>4055-60</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kabasakal]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[AbuQbeitah]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aygün]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yeyin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ocak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Demirci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2015</year>
<volume>42</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1976-83</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sartor]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[de Bono]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chi]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Herrmann]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rahbar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>385</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1091-103</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vassallo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Atlas de incidencia del cáncer en Uruguay &#8211; período 1996-1997]]></source>
<year>2000</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Comisión Honoraria de Lucha contra el Cáncer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kratochwil]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Afshar-Oromieh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kopka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Haberkorn]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Giesel]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator-containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer]]></article-title>
<source><![CDATA[Semin Nucl Med]]></source>
<year>2016</year>
<volume>46</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>405-18</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eder]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schäfer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bauder-Wüst]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Hull]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Wängler]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mier]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging]]></article-title>
<source><![CDATA[Bioconjug Chem]]></source>
<year>2012</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>688-97</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weineisen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schottelius]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Simecek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Baum]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Yildiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beykan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[68Ga- and 177Lu-Labeled PSMA I&amp;T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2015</year>
<volume>56</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1169-76</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baum]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Kulkarni]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[Schuchardt]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wirtz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wiessalla]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: Safety and efficacy]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2016</year>
<volume>57</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1006-13</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmadzadehfar]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Eppard]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kürpig]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fimmers]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yordanova]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schlenkhoff]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2016</year>
<volume>7</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>12477-88</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahbar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Weckesser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Avramovic]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Claesener]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stegger]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer]]></article-title>
<source><![CDATA[Clin Nucl Med]]></source>
<year>2016</year>
<volume>41</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>522-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahbar]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Heinzel]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eppard]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bode]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yordanova]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: A multicenter retrospective analysis]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>2016</year>
<volume>57</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1334-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[von Eyben]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Roviello]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kiljunen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Uprimny]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Virgolini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kairemo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2018</year>
<volume>45</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>496-508</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
